J. P. Novartis, O. N. Munshi, P. G. Richardson, and K. C. , Laubach reports receiving commercial research grants from Celgene, Millennium

G. Org?-un, T. Hideshima, K. C. Anderson, ;. G?-org?-un, K. B. Cowens et al., Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases, Authors' Contributions Conception, vol.1, pp.585-98, 2007.

W. J. Chng, R. Santana-davila, S. A. Van-wier, G. J. Ahmann, S. M. Jalal et al., Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations, Leukemia, vol.20, pp.807-820, 2006.

S. Van-wier, E. Braggio, A. Baker, G. Ahmann, J. Levy et al., Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma, Haematologica, vol.98, pp.1586-92, 2013.

N. V. Smadja, C. Fruchart, F. Isnard, C. Louvet, J. L. Dutel et al., Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases, Leukemia, vol.12, pp.960-969, 1998.

R. Fonseca, C. S. Debes-marun, E. B. Picken, G. W. Dewald, S. C. Bryant et al., The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma, Blood, vol.102, pp.2562-2569, 2003.

G. Gorgun, E. Calabrese, E. Soydan, T. Hideshima, G. Perrone et al., Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma, Blood, vol.116, pp.3227-3264, 2010.

J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-akita et al., B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression, Clin Cancer Res, vol.10, pp.5094-100, 2004.

C. Wu, Y. Zhu, J. Jiang, J. Zhao, X. G. Zhang et al., Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance, Acta Histochem, vol.108, pp.19-24, 2006.

T. Hideshima, C. Mitsiades, M. Akiyama, T. Hayashi, D. Chauhan et al., Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341, Blood, vol.101, pp.1530-1534, 2003.

T. Hideshima, D. Chauhan, Y. Shima, N. Raje, F. E. Davies et al., Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy, Blood, vol.96, pp.2943-50, 2000.

D. Atanackovic, T. Luetkens, and N. Kroger, Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma, Leukemia, vol.28, pp.993-1000, 2014.

G. T. Gorgun, G. Whitehill, J. L. Anderson, T. Hideshima, C. Maguire et al., Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans, Blood, vol.121, pp.2975-87, 2013.

K. Luptakova, J. Rosenblatt, B. Glotzbecker, H. Mills, D. Stroopinsky et al., Lenalidomide enhances anti-myeloma cellular immunity, Cancer Immunol Immunother, vol.62, pp.39-49, 2013.

H. Dong, S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano et al., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, vol.8, pp.793-800, 2002.

H. Ghebeh, S. Mohammed, A. Al-omair, A. Qattan, C. Lehe et al., The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors, Neoplasia, vol.8, pp.190-198, 2006.

Y. Ohigashi, M. Sho, Y. Yamada, Y. Tsurui, K. Hamada et al., Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer, Clin Cancer Res, vol.11, pp.2947-53, 2005.

C. Y. Mu, J. A. Huang, Y. Chen, C. Chen, and X. G. Zhang, High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Med Oncol, vol.28, pp.682-690, 2011.

T. Nomi, M. Sho, T. Akahori, K. Hamada, A. Kubo et al., Clinical significance and therapeutic potential of the programmed death-1 ligand/ programmed death-1 pathway in human pancreatic cancer, Clin Cancer Res, vol.13, pp.2151-2158, 2007.

R. H. Thompson, S. M. Kuntz, B. C. Leibovich, H. Dong, C. M. Lohse et al., Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up, Cancer Res, vol.66, pp.3381-3386, 2006.

R. A. Droeser, C. Hirt, C. T. Viehl, D. M. Frey, C. Nebiker et al., Clinical impact of programmed cell death ligand 1 expression in colorectal cancer, Eur J Cancer, vol.49, pp.2233-2275, 2013.

Y. Zhang, S. Huang, D. Gong, Y. Qin, and Q. Shen, Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8 þ T lymphocytes in human non-small cell lung cancer, Cell Mol Immunol, vol.7, pp.389-95, 2010.

D. M. Benson, C. E. Bakan, A. Mishra, C. C. Hofmeister, Y. Efebera et al., The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody, Blood, vol.116, pp.2286-94, 2010.

Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, EMBO J, vol.11, pp.3887-95, 1992.

T. J. Kearl, W. Jing, J. A. Gershan, and B. D. Johnson, Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma, J Immunol, vol.190, pp.5620-5628, 2013.

J. Rosenblatt, B. Glotzbecker, H. Mills, B. Vasir, D. Tzachanis et al., PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine, J Immunother, vol.34, pp.409-427, 2011.

H. Tamura, M. Ishibashi, T. Yamashita, S. Tanosaki, N. Okuyama et al., Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma, Leukemia, vol.27, pp.464-72, 2013.

C. Zhang, W. Wang, X. Qin, Y. Xu, T. Huang et al., B7-H1 protein vaccine induces protective and therapeutic antitumor responses in SP2/0 myeloma-bearing mice, Oncol Rep, vol.30, pp.2442-2450, 2013.

M. E. Keir, M. J. Butte, G. J. Freeman, and A. H. Sharpe, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, vol.26, pp.677-704, 2008.

K. J. Lafferty and A. J. Cunningham, A new analysis of allogeneic interactions, Aust J Exp Biol Med Sci, vol.53, pp.27-42, 1975.

H. Dong, G. Zhu, K. Tamada, and L. Chen, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, Nat Med, vol.5, pp.1365-1374, 1999.

G. J. Freeman, A. J. Long, Y. Iwai, K. Bourque, T. Chernova et al., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, vol.192, pp.1027-1061, 2000.

R. A. Kyle, M. A. Gertz, T. E. Witzig, J. A. Lust, M. Q. Lacy et al., Review of 1027 patients with newly diagnosed multiple myeloma, Mayo Clin Proc, vol.78, pp.21-33, 2003.

Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo et al., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc Natl Acad Sci U S A, vol.99, pp.12293-12300, 2002.

R. H. Thompson, M. D. Gillett, J. C. Cheville, C. M. Lohse, H. Dong et al., Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target, Proc Natl Acad Sci U S A, vol.101, pp.17174-17183, 2004.

J. Duraiswamy, G. J. Freeman, and G. Coukos, Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer, Cancer Res, vol.73, pp.6900-6912, 2013.

J. Duraiswamy, K. M. Kaluza, G. J. Freeman, and G. Coukos, Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors, Cancer Res, vol.73, pp.3591-603, 2013.

S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, vol.366, pp.2443-54, 2012.

O. Hamid, C. Robert, A. Daud, F. S. Hodi, W. J. Hwu et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, vol.369, pp.134-178, 2013.

F. S. Hodi and /. Hematology, Oncology Clinics of North America. Melanoma. Preface. Hematol Oncol Clin North Am, vol.28, pp.xiii-xiv, 2014.

T. K. Choueiri, A. P. Fay, K. P. Gray, M. Callea, T. H. Ho et al., PD-L1 expression in non-clear cell renal cell carcinoma, Ann Oncol, vol.25, pp.2178-84, 2014.

H. Kronig, L. Kremmler, B. Haller, C. Englert, C. Peschel et al., Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment, Eur J Haematol, vol.92, pp.195-203, 2014.

P. Greaves and J. G. Gribben, The role of B7 family molecules in hematologic malignancy, Blood, vol.121, pp.734-778, 2013.

Y. Hao, B. Chapuy, S. Monti, H. H. Sun, S. J. Rodig et al., Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo, Clin Cancer Res, vol.20, pp.2674-83, 2014.

D. Rossille, M. Gressier, D. Damotte, D. Maucort-boulch, C. Pangault et al., High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial, Leukemia, vol.28, pp.2367-75, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00981338

S. M. Ansell, A. M. Lesokhin, I. Borrello, A. Halwani, E. C. Scott et al., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, vol.372, pp.311-320, 2015.

B. Huang, P. Y. Pan, Q. Li, A. I. Sato, D. E. Levy et al., Gr-1 þ CD115 þ immature myeloid suppressor cells mediate the development of tumorinduced T regulatory cells and T-cell anergy in tumor-bearing host, Cancer Res, vol.66, pp.1123-1154, 2006.

T. Fujimura, S. Ring, V. Umansky, K. Mahnke, and A. H. Enk, Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas, J Invest Dermatol, vol.132, pp.1239-1285, 2012.

Y. Liu, B. Zeng, Z. Zhang, Y. Zhang, and R. Yang, B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer, Clin Immunol, vol.129, pp.471-81, 2008.

J. Favaloro, T. Liyadipitiya, R. Brown, S. Yang, H. Suen et al., Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma, Clin Cancer Res Güllü Görgün, vol.2014, pp.4607-4618, 2015.